A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2011
At a glance
- Drugs Daptomycin (Primary)
- Indications Bacterial endocarditis; Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 27 Sep 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 Oct 2010 New trial record